Frontiers in Clinical Drug Research: Diabetes and Obesity

Volume: 1

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Angiotensin Blockers and Renoprotection in Diabetic Chronic Kidney Disease is a Failed Paradigm? – A Revisionist View of Renoprotection in Diabetic Chronic Kidney Disease and A Novel Classification Scheme for Renoprotective Agents

Pp. 3-32 (30)

Macaulay A.C. Onuigbo

Abstract

The excellent innovative work of Squibb Laboratory scientists in the 1970’s led to the discovery of the ACE inhibitors and the ARBs. Despite their widespread use, for renoprotection, we have continued to experience a global ESRD pandemic. Angiotensin blockade has proved inadequate. In 2010, we asked the rhetorical question: Is renoprotection with RAAS blockade a failed paradigm?

Keywords:

Angiotensin receptor blockers, ACE inhibitors, chronic kidney disease, diabetes mellitus, novel classification scheme, revisionist view, renoprotection, renoprotective agents.

Affiliation:

College of Medicine, Mayo Clinic, Rochester, MN, Luther Midelfort Site, Mayo Health System Practice-Based Research Network (MHS PBRN), Department of Nephrology, Mayo Clinic Health System Eau Claire, 1221 Whipple Street, Eau Claire, WI 54702., MBA Healthcare Executive, USA.